Trial record 18 of 37 for:
Open Studies | "Tinnitus"
Tinnitus Measured by MEG and Synchronous Neural Interaction™ Test: Template Development
The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2011 by Orasi Medical, Inc..
Recruitment status was Recruiting
Information provided by:
Orasi Medical, Inc.
First received: August 17, 2010
Last updated: March 22, 2011
Last verified: March 2011
The study is designed to identify specific patterns of brain functional activity associated with chronic, moderate to severe tinnitus through the use of resting-state MEG scans. Robust patterns identified in this study will be used as a biomarker for subsequent clinical evaluation of experimental drug treatments for tinnitus. This study will conduct MEG scans on approximately 30 to 75 subjects with tinnitus and approximately 15 healthy control subjects. MEG scans will be obtained for each subject following screening, clinical and tinnitus evaluations. A subset of 6 subjects from the tinnitus cohort will be invited to undergo evoked auditory assessment during an extended MEG scan session to identify cortical regions that respond to the auditory stimulus. These six subjects also will be evaluated with a single structural MRI scan to support high-resolution mapping of the localized cortical regions. MEG data will be analyzed to identify patterns of brain activity that are specifically associated with the presence of tinnitus using both standard approaches and the Orasi Synchronous Neural Interaction™ (SNI) test. MEG scan results also will be evaluated to identify specific patterns of functional activity that correlate with other measures of tinnitus severity such as the Iowa Tinnitus Handicap Scale. This study will test the hypothesis that moderate to severe tinnitus is associated with altered patterns of brain functional activity measured by a brief, resting-state MEG scan. This hypothesis will be tested by comparing resting-state MEG scans of tinnitus patients with those the of healthy control subjects collected during this study and available in Orasi's existing MEG scan database.
||Observational Model: Case Control
Time Perspective: Cross-Sectional
||Moderate to Severe Tinnitus as Measured by MEG and the Synchronous Neural Interaction™ Test: Template Development Study
Primary Outcome Measures:
Secondary Outcome Measures:
| Estimated Enrollment:
| Study Start Date:
| Estimated Study Completion Date:
| Estimated Primary Completion Date:
||August 2011 (Final data collection date for primary outcome measure)
Subjects with chronic, moderate to severe unilateral tinnitus.
Healthy control subjects
|Ages Eligible for Study:
||18 Years to 75 Years
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
Subjects with chronic, moderate to severe unilateral tinnitus
- Subject is between 18 and 75 years of age at the time of screening.
- Subject understands the study procedures and agrees to participate in the study by giving written informed consent.
- Subject is a non-smoker.
- Subject is judged to be in good health based on medical history and brief physical examination.
- Subject has a diagnosis of chronic, moderate to severe (Tinnitus Handicap Inventory score range of 38 - 76, inclusive), unilateral tinnitus of unknown etiology, or is participating in the study as a healthy control subject.
- Subject has severe hearing impairment, external or middle ear diseases or temporomandibular joint disorders.
- Subject has a diagnosis of a significant neurological condition including Alzheimer's disease, Parkinson's disease, vascular dementia, Lewy body dementia or frontal temporal dementia, human immunodeficiency virus, multiple sclerosis, or severe traumatic brain injury.
- Subject has a history of primary psychotic disorder (e.g. schizophrenia, schizoaffective disorder, delusional disorder) or bipolar disorder.
- Subject has a history of seizures, epilepsy, stroke, peripheral neuropathy, head trauma with persistent post-concussive symptoms, ADHD, dyslexia or other clinically significant neurological disease or cognitive impairment.
- Subject has a current episode of major depressive disorder.
- Subject has used antidepressants, anxiolytics, antipsychotics or antiepileptic medications in the past 6 months.
- Subject has a recent (within 2 years) history of alcohol or substance abuse/dependence.
- Subject has completed an MRI within 2 weeks prior to the MEG scan.
- Subject has metal braces or pacemaker that may interfere with the MEG scan.
- Subject is unable to complete the MEG scan procedure.
- The investigator has any concern regarding the safe participation of a subject in the study, or if for any other reason the investigator considers the subject inappropriate for study participation
Please refer to this study by its ClinicalTrials.gov identifier: NCT01185990
|Noran Neurological Clinic
|Minneapolis, Minnesota, United States, 55407 |
|Contact: Ann Rechtzigel, BSN 612-708-5357 email@example.com |
|Principal Investigator: Richard E Golden, MD |
|Minneapolis, Minnesota, United States, 55435 |
|Contact: Anne-Marie Tschida 952-922-7000 ext 4640 firstname.lastname@example.org |
|Principal Investigator: Tami Helmer, MD |
Orasi Medical, Inc.
||Richard E Golden, MD
||Noran Neurological Clinic
||Tami Helmer, MD
No publications provided
||Todd Verdoorn, PhD, Chief Scientific Officer, Orasi Medical, Inc.
History of Changes
|Other Study ID Numbers:
||TTD 10 - 01
|Study First Received:
||August 17, 2010
||March 22, 2011
||United States: Institutional Review Board
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on March 05, 2014
Nervous System Diseases
Signs and Symptoms